UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2004
OR
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 1-5975
HUMANA INC.
(Exact name of registrant as specified in its charter)
| Delaware | 61-0647538 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
500 West Main Street
Louisville, Kentucky 40202
(Address of principal executive offices, including zip code)
(502) 580-1000
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes x No ¨
Indicate the number of shares outstanding of each of the issuers classes of common stock as of the latest practicable date.
| Class of Common Stock |
Outstanding at October 31, 2004 | |
| $0.16 2/3 par value | 159,407,737 shares |
FORM 10-Q
SEPTEMBER 30, 2004
INDEX
| Page | ||||
| Part I: Financial Information | ||||
| Item 1. |
||||
| Condensed Consolidated Balance Sheets at September 30, 2004 and December 31, 2003 |
3 | |||
| 4 | ||||
| 5 | ||||
| 6 | ||||
| Item 2. |
Managements Discussion and Analysis of Financial Condition and Results of Operations |
18 | ||
| Item 3. |
37 | |||
| Item 4. |
37 | |||
| Part II: Other Information | ||||
| Item 1. |
38 | |||
| Item 2. |
38 | |||
| Item 6. |
38 | |||
| 40 | ||||
2
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| September 30, 2004 |
December 31, 2003 |
|||||||
| (in thousands, except share amounts) | ||||||||
| ASSETS |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 375,090 | $ | 931,404 | ||||
| Investment securities |
2,332,522 | 1,676,642 | ||||||
| Receivables, less allowance for doubtful accounts of $29,475 at September 30, 2004 and $40,400 at December 31, 2003: |
||||||||
| Premiums |
405,067 | 452,404 | ||||||
| Administrative services fees |
19,803 | 13,583 | ||||||
| Other |
273,240 | 247,298 | ||||||
| Total current assets |
3,405,722 | 3,321,331 | ||||||
| Property and equipment, net |
390,735 | 416,472 | ||||||
| Other assets: |
||||||||
| Long-term investment securities |
333,796 | 319,167 | ||||||
| Goodwill |
859,734 | 776,874 | ||||||
| Other |
421,623 | 459,479 | ||||||
| Total other assets |
1,615,153 | 1,555,520 | ||||||
| Total assets |
$ | 5,411,610 | $ | 5,293,323 | ||||
| LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
| Current liabilities: |
||||||||
| Medical and other expenses payable |
$ | 1,436,135 | $ | 1,272,156 | ||||
| Trade accounts payable and accrued expenses |
504,892 | 440,340 | ||||||
| Book overdraft |
116,106 | 219,054 | ||||||
| Unearned revenues |
132,659 | 333,071 | ||||||
| Total current liabilities |
2,189,792 | 2,264,621 | ||||||
| Long-term debt |
630,912 | 642,638 | ||||||
| Other long-term liabilities |
568,911 | 550,115 | ||||||
| Total liabilities |
3,389,615 | 3,457,374 | ||||||
| Commitments and contingencies |
||||||||
| Stockholders equity: |
||||||||
| Preferred stock, $1 par; 10,000,000 shares authorized, none issued |
| | ||||||
| Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 175,062,193 shares issued at September 30, 2004 and 173,909,127 shares issued at December 31, 2003 |
29,177 | 28,984 | ||||||
| Capital in excess of par value |
994,975 | 974,975 | ||||||
| Retained earnings |
1,182,697 | 949,811 | ||||||
| Accumulated other comprehensive income |
13,797 | 16,909 | ||||||
| Unearned stock compensation |
(203 | ) | (754 | ) | ||||
| Treasury stock, at cost, 15,689,251 shares at September 30, 2004 and 12,018,281 shares at December 31, 2003 |
(198,448 | ) | (133,976 | ) | ||||
| Total stockholders equity |
2,021,995 | 1,835,949 | ||||||
| Total liabilities and stockholders equity |
$ | 5,411,610 | $ | 5,293,323 | ||||
See accompanying notes to condensed consolidated financial statements.
3
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
| Three months ended September 30, |
Nine months ended September 30, | |||||||||||
| 2004 |
2003 |
2004 |
2003 | |||||||||
| (in thousands, except per share results) | ||||||||||||
| Revenues: |
||||||||||||
| Premiums |
$ | 3,083,554 | $ | 3,016,298 | $ | 9,566,447 | $ | 8,772,652 | ||||
| Administrative services fees |
59,837 | 66,984 | 219,420 | 199,788 | ||||||||
| Investment and other income |
32,882 | 28,483 | 108,833 | 100,999 | ||||||||
| Total revenues |
3,176,273 | 3,111,765 | 9,894,700 | 9,073,439 | ||||||||
| Operating expenses: |
||||||||||||
| Medical |
2,550,911 | 2,528,123 | 8,024,167 | 7,344,534 | ||||||||
| Selling, general and administrative |
460,171 | 458,381 | 1,416,695 | 1,371,196 | ||||||||
| Depreciation and amortization |
31,238 | 27,112 | 84,715 | 100,232 | ||||||||
| Total operating expenses |
3,042,320 | 3,013,616 | 9,525,577 | 8,815,962 | ||||||||
| Income from operations |
133,953 | 98,149 | 369,123 | 257,477 | ||||||||
| Interest expense |
6,480 | 4,737 | 16,524 | 12,473 | ||||||||
| Income before income taxes |
127,473 | 93,412 | 352,599 | 245,004 | ||||||||
| Provision for income taxes |
43,170 | 31,293 | 119,713 | 82,379 | ||||||||
| Net income |
$ | 84,303 | $ | 62,119 | $ | 232,886 | $ | 162,625 | ||||
| Basic earnings per common share |
$ | 0.53 | $ | 0.39 | $ | 1.45 | $ | 1.03 | ||||
| Diluted earnings per common share |
$ | 0.52 | $ | 0.38 | $ | 1.43 | $ | 1.01 | ||||
See accompanying notes to condensed consolidated financial statements.
4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| For the nine months ended September 30, |
||||||||
| 2004 |
2003 |
|||||||
| (in thousands) | ||||||||
| Cash flows from operating activities |
||||||||
| Net income |
$ | 232,886 | $ | 162,625 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
| Writedown of property and equipment |
| 17,233 | ||||||
| Depreciation and amortization |
84,715 | 100,232 | ||||||
| Provision for deferred income taxes |
27,545 | 30,213 | ||||||
| Changes in operating assets and liabilities, net of effect of business acquired: |
||||||||
| Receivables |
106,709 | 13,516 | ||||||
| Other assets |
(18,776 | ) | 42,435 | |||||
| Medical and other expenses payable |
92,916 | 154,435 | ||||||
| Other liabilities |
26,675 | (151,363 | ) | |||||
| Unearned revenues |
(204,426 | ) | (227,596 | ) | ||||
| Other, net |
(19,920 | ) | (18,810 | ) | ||||
| Net cash provided by operating activities |
328,324 | 122,920 | ||||||
| Cash flows from investing activities |
||||||||
| Acquisition, net of cash and cash equivalents acquired |
(115,972 | ) | | |||||
| Purchases of property and equipment |
(72,900 | ) | (64,980 | ) | ||||
| Proceeds from sales of property and equipment |
28,972 | 2,483 | ||||||
| Purchases of investment securities |
(3,614,781 | ) | (3,659,394 | ) | ||||
| Maturities of investment securities |
840,275 | 585,461 | ||||||
| Proceeds from sales of investment securities |
2,203,853 | 2,768,446 | ||||||
| Net cash used in investing activities |
(730,553 | ) | (367,984 | ) | ||||
| Cash flows from financing activities |
||||||||
| Net commercial paper conduit repayments |
| (265,000 | ) | |||||
| Proceeds from issuance of senior notes |
| 299,139 | ||||||
| Common stock repurchases |
(64,472 | ) | (44,147 | ) | ||||
| Proceeds from swap exchange |
| 31,556 | ||||||
| Change in book overdraft |
(102,948 | ) | 123,869 | |||||
| Proceeds from stock option exercises and other |
13,335 | 14,127 | ||||||
| Net cash (used in) provided by financing activities |
(154,085 | ) | 159,544 | |||||
| Decrease in cash and cash equivalents |
(556,314 | ) | (85,520 | ) | ||||
| Cash and cash equivalents at beginning of period |
931,404 | 721,357 | ||||||
| Cash and cash equivalents at end of period |
$ | 375,090 | $ | 635,837 | ||||
| Supplemental cash flow disclosures: |
||||||||
| Interest payments |
$ | 22,663 | $ | 11,324 | ||||
| Income tax payments, net |
$ | 44,922 | $ | 43,335 | ||||
See accompanying notes to condensed consolidated financial statements.
5
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Unaudited
(1) Basis of Presentation
The accompanying condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or those normally made in an Annual Report on Form 10-K. References throughout this document to we, us, our, the Company, and Humana, mean Humana Inc. and all entities we own. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2003, that was filed with the Securities and Exchange Commission, or the SEC, on March 5, 2004.
The preparation of our condensed consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of medical expenses payable, the recognition of revenue related to our TRICARE contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill. Although our estimates are based on knowledge of current events and anticipated future events, actual results may ultimately differ materially from those estimates. Refer to Critical Accounting Policies and Estimates in Humanas 2003 Annual Report on Form 10-K for information on accounting policies that the Company considers critical in preparing its Consolidated Financial Statements.
The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.
(2) Significant Accounting Policies
Stock-Based Compensation
We have stock-based employee compensation plans, which are described more fully in Note 10 to the consolidated financial statements in Humanas 2003 Annual Report on Form 10-K. We account for our stock option plans under Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees and related interpretations, or APB No. 25. No employee compensation cost is reflected in net income related to fixed-based stock option awards because these options had an exercise price equal to the market value of the underlying common stock on the date of grant. Generally, if a fixed-based stock option award is subsequently modified, compensation expense, if any, is recorded for the amount that the market price of Humana common stock exceeds the options exercise price on the date the option is modified. Compensation expense is recorded for restricted stock grants over their vesting periods based on fair value, which is equal to the market price of Humana common stock on the date of the grant.
6
Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Continued)
Unaudited
The effect on net income and earnings per share if we had applied the fair value recognition provisions of Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation, to our fixed-based stock option and restricted stock awards was as follows for the three and nine months ended September 30, 2004 and 2003.
| Three months ended September 30, |
Nine months ended September 30, |
|||||||||||||||
| 2004 |
||||||||||||||||